Earnings History Data for Madrigal Pharmaceuticals, Inc. (MDGL) - NYSE NASDAQ

To lookup another company type a stock symbol and press 'Go'. The overview will show the earnings release info that is available in TheStockCatalyst database for the company.

For historic stock the Extended Hours price data shown are from just before market open on the day of release for premarket earnings releases and of the day after release for afterhours earnings releases. The normal price data is from just before market close on the days of release for premarket releases and the day after release for afterhours releases.

See the full list of available companies here.

Madrigal Pharmaceuticals, Inc.

Madrigal Pharmaceuticals, Inc. is engaged in developing small-molecule drugs addressing cardiovascular and metabolic diseases. Its products pipeline include MGL-3196, an orally administered liver-directed thyroid hormone receptor-? agonist that is used for the treatment of NASH, dyslipidemia/hypercholesterolemia and high triglycerides; and MGL-3745, a thyroid hormone receptor-? agonist which are in pre-clinical trial stage. Madrigal Pharmaceuticals Inc., formerly known as Synta Pharmaceuticals Corp., is based in Fort Washington, Pennsylvania.

Release Date	Time	Est. Time	Symbol	Name	Market Cap (M)	Rep. EPS	Est. EPS	Last years EPS	SeekingAlpha Headline	Price	Change	Ext. Hours Price	Ext. Hours Change	52 Week Range	Volume	Avg. Volume	Ext. Hours Volume
05-08-2025	PM		MDGL	Madrigal Pharmaceuticals, Inc.	6,710	-1.90	-3.48	-7.10	Madrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M [8/5/2025 7:06 AM]	338.40	26.29 (8.42%)	348.65	36.54 (11.71%)	200.63 - 377.46	1,009,309	390,000	32,917
Madrigal Pharmaceuticals Q2 2025 Earnings Preview [8/4/2025 10:58 AM] Madrigal Pharmaceuticals, Inc. GAAP EPS of -$1.90 beats by $1.51, revenue of $212.8M beats by $50.63M [8/5/2025 7:06 AM] Madrigal jumps as MASH drug Rezdiffra drives massive Q2 beat [8/5/2025 3:28 PM]
01-05-2025	PM		MDGL	Madrigal Pharmaceuticals, Inc.	7,520	-3.32	-3.62	-7.38	Madrigal Pharmaceuticals GAAP EPS of -$3.32 beats by $0.41, revenue of $137.3M beats by $23.11M [5/1/2025 7:05 AM]	326.22	-7.69 (-2.30%)	341.11	7.20 (2.16%)	200.08 - 377.46	717,396	0	3,514
Madrigal Pharmaceuticals, Inc. Q1 2025 Earnings Preview [4/30/2025 3:04 PM] Madrigal Pharmaceuticals GAAP EPS of -$3.32 beats by $0.41, revenue of $137.3M beats by $23.11M [5/1/2025 7:05 AM] Madrigal Pharmaceuticals advances Rezdiffra market penetration with 33% quarterly sales growth [5/1/2025 1:02 PM] Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates [2025-05-01 07:00AM]
26-02-2025	PM		MDGL	Madrigal Pharmaceuticals, Inc.	7,030	-2.71	-4.12	-5.68	Madrigal Pharmaceuticals, Inc. GAAP EPS of -$2.71 beats by $1.39, revenue of $103.32M beats by $5.51M [2/26/2025 7:02 AM]	355.92	46.43 (15.00%)	330.00	20.51 (6.63%)	189.00 - 377.46	1,046,844	330,000	1,078
Madrigal Pharmaceuticals, Inc. Q4 2024 Earnings Preview [2/25/2025 1:04 PM] Madrigal Pharmaceuticals, Inc. GAAP EPS of -$2.71 beats by $1.39, revenue of $103.32M beats by $5.51M [2/26/2025 7:02 AM] Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis [2025-02-26 07:00AM] Madrigal Announces New Two-Year Data from the Compensated MASH Cirrhosis Arm of the MAESTRO-NAFLD-1 Trial Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis [2025-02-26 06:30AM]
31-10-2024	PM		MDGL	Madrigal Pharmaceuticals, Inc.	4,730	-4.92	-6.94	-5.34	Madrigal Pharmaceuticals GAAP EPS of -$4.92 beats by $2.00, revenue of $62.2M beats by $27.79M [10/31/2024 7:06 AM]	260.94	45.01 (20.84%)	244.27	28.34 (13.12%)	125.57 - 299.98	1,196,144	280,000	43,452
Madrigal Pharmaceuticals Q3 2024 Earnings Preview [10/30/2024 11:18 AM] Madrigal Pharmaceuticals GAAP EPS of -$4.92 beats by $2.00, revenue of $62.2M beats by $27.79M [10/31/2024 7:06 AM] Madrigal stock jumps 13% after Rezdiffra Q3 sales beat estimates [10/31/2024 9:54 AM] Madrigal Pharmaceuticals Reports Third-Quarter 2024 Financial Results and Provides Corporate Updates [2024-10-31 07:00AM] Madrigal Pharmaceuticals to Present Multiple Rezdiffra (resmetirom) Abstracts in NASH/MASH at the AASLD Liver Meeting [Oct-30-24 08:00AM] Madrigal: Q3 Earnings Snapshot [2024-10-31 07:28AM]
07-08-2024	PM		MDGL	Madrigal Pharmaceuticals, Inc.	5,870	-7.10	-7.55	-4.69	Madrigal Pharmaceuticals GAAP EPS of -$7.10 beats by $0.51, revenue of $14.6M beats by $10.22M [8/7/2024 7:05 AM]	234.60	-31.96 (-11.99%)	249.00	-17.56 (-6.59%)	119.76 - 299.98	1,228,989	240,000	19,600
Madrigal Pharmaceuticals Q2 2024 Earnings Preview [8/6/2024 12:09 PM] Madrigal Pharmaceuticals GAAP EPS of -$7.10 beats by $0.51, revenue of $14.6M beats by $10.22M [8/7/2024 7:05 AM] Madrigal falls despite massive Q2 revenue beat [8/7/2024 10:58 AM]
07-05-2024	PM		MDGL	Madrigal Pharmaceuticals	4,599	-7.38	-6.06	0.00	Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18 [5/7/2024 7:04 AM]	217.62	-17.95 (-7.62%)	222.00	-13.57 (-5.76%)	119.76 - 313.11	711,046	470,000	4,500
Madrigal Pharmaceuticals GAAP EPS of -$7.38 misses by $1.18 [5/7/2024 7:04 AM] Madrigal Pharmaceuticals Q1 2024 Earnings Preview [5/6/2024 10:57 AM] Madrigal sees ‘tremendous interest’ in new NASH drug Rezdiffra [5/7/2024 10:44 AM]
28-02-2024	PM		MDGL	Madrigal Pharmaceuticals	4,592	-5.68	-5.32	0.00	Madrigal Pharmaceuticals GAAP EPS of -$5.68 misses by $0.42 [2/28/2024 7:24 AM]	253.95	14.15 (5.90%)	0.0	0.0 (0.00%)	119.76 - 322.67	417,688	520,000	0
Madrigal Pharmaceuticals GAAP EPS of -$5.68 misses by $0.42 [2/28/2024 7:24 AM] Madrigal Pharmaceuticals names Mardi Dier as CFO [2/28/2024 7:54 AM]
06-11-2023	PM		MDGL	Madrigal Pharmaceuticals	2,538	-5.34	-4.78	0.00		147.40	0.51 (0.35%)	0.0	0.0 (0.00%)	57.21 - 322.67	327,436	410,000	0

08-08-2023	PM		MDGL	Madrigal Pharmaceuticals	3,557	-4.69	-4.47	0.00	Madrigal Pharmaceuticals GAAP EPS of -$4.69 [8/8/2023 9:00 AM]	169.01	-10.48 (-5.84%)	175.01	-4.48 (-2.50%)	57.21 - 322.67	873,604	240,000	5,328
Madrigal Pharmaceuticals GAAP EPS of -$4.69 [8/8/2023 9:00 AM]
09-05-2022	PM	8:00 AM ET (May 9)	MDGL	Madrigal Pharmaceuticals, Inc.	1,140	-3.36	-3.75	-3.32	Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20 [5/9/2022 6:32 AM]	57.55	-7.04 (-10.90%)	64.59	0.0 (0.00%)	52.33 - 137.78	416,356	220,000	21,884
Madrigal Pharmaceuticals GAAP EPS of -$3.36 beats by $0.20 [5/9/2022 6:32 AM] Madrigal Pharmaceuticals Provides Clinical and Business Updates and Reports 2022 First Quarter Financial Results [May-09-22 06:30AM] We're Keeping An Eye On Madrigal Pharmaceuticals' (NASDAQ:MDGL) Cash Burn Rate [May-09-22 09:45AM]
06-05-2021	PM		MDGL	Madrigal Pharmaceuticals, Inc.	2,150	-3.32	-3.78	-2.34	Madrigal Pharmaceuticals EPS beats by $0.44 [5/6/2021 6:58 AM]	126.71	-2.85 (-2.20%)	126.71	0.0 (0.00%)	85.52 - 142.62	146,670	90,000	521
Madrigal Pharmaceuticals EPS beats by $0.44 [5/6/2021 6:58 AM] Madrigal Pharmaceuticals Reports 2021 First Quarter Financial Results and Highlights [May-06-21 06:50AM]
25-02-2021	PM		MDGL	Madrigal Pharmaceuticals, Inc.	1,840	-3.82	-3.82	-1.80	Madrigal Pharmaceuticals EPS beats by $0.16 [2/25/2021 6:53 AM]	122.80	2.61 (2.17%)	122.80	0.0 (0.00%)	56.82 - 137.28	140,195	164,622	5,732
Madrigal Pharmaceuticals EPS beats by $0.16 [2/25/2021 6:53 AM] Madrigal Pharmaceuticals Reports 2020 Fourth Quarter and Full Year Financial Results and Highlights [Feb-25-21 06:50AM]
05-11-2020	PM		MDGL	Madrigal Pharmaceuticals, Inc.	1,970	-3.75	-3.35	-1.39	Madrigal Pharmaceuticals EPS misses by $0.40 [11/5/2020 7:39 AM]	132.99	4.99 (3.90%)	132.99	0.0 (0.00%)	56.82 - 137.28	205,137	98,992	3,326

06-08-2020	PM		MDGL	Madrigal Pharmaceuticals, Inc.	1,580	-3.18	-2.42	-1.28	Madrigal Pharmaceuticals EPS misses by $0.74 [8/6/2020 7:52 AM]	101.49	-4.93 (-4.63%)	106.42	0.0 (0.00%)	56.82 - 127.25	59,071	81,348	1,711